miRNA-193a FOR PROMOTING IMMUNOGENIC CELL DEATH

The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a CRT agonist, promoting the cell surface expression of CRT. This allows the advantageous treatment of cancers without or with low surface expression of CRT. The inventi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	JANICOT, Michel, YAHYANEJAD, Sanaz, VAN PINXTEREN, Laurens Adrianus Hendricus, DE GUNST, Matheus Maria, TELFORD, Bryony, SCHAAPVELD, Roeland Quirinus Jozef, VAN DEN BOSCH, Marion, ALEMDEHY, Mir Farshid
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a CRT agonist, promoting the cell surface expression of CRT. This allows the advantageous treatment of cancers without or with low surface expression of CRT. The invention further relates to compositions comprising the miRNA for use in such treatment. L'invention concerne l'utilisation de miARN-193a pour réguler l'expression génique, en particulier l'utilisation de miARN-193a en tant qu'agoniste de la CRT, favorisant l'expression de surface cellulaire de la CRT. Cela permet le traitement avantageux de cancers sans ou avec une faible expression de surface de la CRT. L'invention concerne en outre des compositions comprenant le miARN destiné à être utilisé dans un tel traitement.